This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-new-glaucoma-drug-study-is-starting-could-an-oral-cannabinoid-help-lower-eye-pressure

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A New Glaucoma Drug Study Is Starting: Could an Oral Cannabinoid Help Lower Eye Pressure?Some patients may have seen news on March 18, 2026 about a new drug trial for glaucoma and wondered what it means. It’s about a medicine called ART27.13, an experimental oral drug aimed at lowering eye pressure in people with glaucoma or ocular hypertension. In simple terms, this is only a research study. The drug is not FDA-approved or proven to work yet. It is being tested to see if it can safely lower the pressure inside the eye. Before we dive in, let’s remember why eye pressure matters. Glaucoma is a group of eye conditions where high pressure or poor blood flow damages the optic nerve at the back of the eye. That nerve damage causes vision loss. Once vision is lost from glaucoma, it cannot be restored () (). So doctors focus on slowing the damage, not fixing it. The only proven way to slow glaucoma is by lowering the pressure in the eye (). Today this is usually done with eye drops or surgery. A new study is exploring whether ART27.13, an oral drug, can join these treatments. What Is ART27.13?ART27.13 is the code name for a new experimental drug. It is related to cannabinoids – the kinds of active compounds found in the cannabis plant – but it is specially made in a lab. It is taken by mouth (an oral tablet). The reason researchers are interested is that some cannabinoids can lower eye pressure. However, ART27.13 is not just cannabis. It is designed to work mainly outside the brain. In other words, it should not make someone feel high or have the same effects as marijuana. Scientists hope it targets only the eye and body tissues involved in pressure. No one can take ART27.13 outside a doctor’s study right now – it’s only being given to volunteers in the trial. Remember: this is early clinical research. ART27.13 is not an approved medicine yet. It is being studied to see if it is safe and if it can lower eye pressure. We do not know if it will help; that is exactly what the trial is meant to find out. Why Are Cannabinoids of Interest in Glaucoma?Cannabinoids have a long history in glaucoma research. Many people know that marijuana can lower eye pressure a bit (at least for a few hours). In fact, cannabis and related compounds have been known since the 1970s to temporarily reduce intraocular pressure (). Studies show that taking THC or synthetic cannabinoids by mouth can drop pressure by up to about 10–30%, but only for a few hours (). After that, the pressure goes back up. (One review found the maximum drop at 2–4 hours after dose, and it stopped in 3–4 hours () ().) Because of this, some researchers wondered if certain cannabinoids could help with glaucoma. Cannabinoids also have other effects that might help: they can improve blood flow to the optic nerve and may reduce inflammation. But there are problems with using ordinary cannabis. The drop in eye pressure is short-lived and would require dosing many times a day () (). Meanwhile, marijuana causes side effects like feeling “high,” tiredness, and faster heartbeat. Because of that, eye doctors do not use medical cannabis to treat glaucoma. As one eye specialist explained, most glaucoma doctors believe “marijuana is really ineffective” for tre

Support the show